Predictors of LDL-C target non-attainment in patients with type 2 diabetes with obesity and very high cardiovascular risk

Cao Dinh Hung, Bui Minh Tri, Tran Phuc Loc, Nguyen Thi Thu Thao, Ma Ry, Nguyen Quang Minh

Main Article Content

Abstract

Type 2 diabetes mellitus (T2DM) is a metabolic disorder that increases the risk of atherosclerotic cardiovascular disease, particularly in obese patients. Controlling low-density lipoprotein cholesterol (LDL-C) is the key therapeutic target in reducing cardiovascular risk. However, domestic data on factors influencing LDL-C goal attainment in this population remain limited. A cross-sectional study was conducted on 138 obese T2DM patients treated with statins for at least 3 months at Nguyen Tri Phuong Hospital from April 2024 to October 2024. Results showed that 120 patients (86.9%) did not achieve the LDL-C goal, of whom 89.7% had central obesity. Central obesity was identified as a predictor of LDL-C goal non-attainment (odds ratio [OR] = 3.782; 95% confidence interval [CI]: 1.123 – 12.740), whereas high treatment adherence assessed by the Morisky-8 scale was significantly reducing this risk (OR = 0.196; 95% CI: 0.041 – 0.944). These findings highlight the importance of managing central obesity and strengthening treatment adherence strategies to improve LDL-C control in obese T2DM patients.

Article Details

References

1. Global Diabetes Data & Insights | IDF Diabetes Atlas. https://diabetesatlas.org/data-by-location/global/. Accessed October 14, 2025.
2. Klop B, Elte JWF, Castro Cabezas M. Dyslipidemia in Obesity: Mechanisms and Potential Targets. Nutrients. 2013; 5(4): 1218-1240. doi:10.3390/nu5041218.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The task force for the management of dyslipidaemias of the european society of cardiology (ESC) and european atherosclerosis society (EAS). European Heart Journal. 2019; 41(1): 111-188. doi:10.1093/eurheartj/ehz455.
4. Zhou X, Ji L, Ran X, et al. Prevalence of Obesity and Its Influence on Achievement of Cardiometabolic Therapeutic Goals in Chinese Type 2 Diabetes Patients: An Analysis of the Nationwide, Cross-Sectional 3B Study. PLoS One. 2016; 11(1): e0144179. doi:10.1371/journal.pone.0144179.
5. Nguyen HT, Ha KPT, Nguyen AH, Nguyen TT, Lam HM. Non-achievement of the Low-Density Lipoprotein Cholesterol Goal in Older Patients with Type 2 Diabetes Mellitus and a Very High Cardiovascular Disease Risk: A Multicenter Study in Vietnam. Ann Geriatr Med Res. 2021; 25(4): 278-285. doi:10.4235/agmr.21.0099.
6. Committee ADAPP. 2. Diagnosis and classification of diabetes: Standards of care in diabetes-2024. Diabetes Care. 2023; 47(Supplement_1): S20-S42. doi:10.2337/dc24-S002.
7. Organization WH, others. The Asia-Pacific perspective: redefining obesity and its treatment. http://www who int/bmi/index jsp? introPage= intro_3 html. 2000.
8. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the european society of cardiology (ESC) and the european society of hypertension (ESH). European Heart Journal. 2018; 39(33): 3021-3104. doi:10.1093/eurheartj/ehy339.
9. Trường PH, Khoa ĐĐ, Khánh VHX, Anh NH, Hải NH. Cập nhật chẩn đoán và điều trị suy tim phân suất tống máu bảo tồn: 1. 2024; 3(1): 12-12.
10. Ibrahim A. IDF Clinical Practice Recommendation on the Diabetic Foot: A guide for healthcare professionals. Diabetes Res Clin Pract. 2017; 127: 285-287. doi:10.1016/j.diabres.2017.04.013.
11. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6): 2089-2100. doi:10.1111/j.1523-1755.2005.00365.x.
12. Eknoyan G, Lameire N, Eckardt KU, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements. 2013; 3(1): 5-14. doi:10.1038/kisup.2012.73.
13. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403): 157-163. doi:10.1016/S0140-6736(03)15268-3.
14. Grover A, Oberoi M, Rehan HS, Gupta LK, Yadav M. Self-reported Morisky Eight-item Medication Adherence Scale for Statins Concords with the Pill Count Method and Correlates with Serum Lipid Profile Parameters and Serum HMGCoA Reductase Levels. Cureus. 12(1): e6542. doi:10.7759/cureus.6542.
15. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. August 2025: ehaf190. doi:10.1093/eurheartj/ehaf190.
16. The Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011; 377(9784): 1085-1095. doi:10.1016/S0140-6736(11)60105-0.
17. Tsai HS, Tseng WK, Yin WH, et al. The Correlation between Waist-Hip Ratio and Achieving Therapeutic Lipid Goals in Taiwan. Acta Cardiol Sin. 2019; 35(6): 605-614. doi:10.6515/ACS.201911_35(6).20190403A.
18. S CM, Vijaykumar S, G PA. Type 2 diabetes mellitus with dyslipidemia: risk factors, prevalence, pathophysiology, and nutritional management-a narrative review. International Journal Of Community Medicine And Public Health. 2025; 12(6): 2900-2908. doi:10.18203/2394-6040.ijcmph20251741.